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Abstract
Laboratory diagnosis and clinical management of inpatients with diarrhoea is complex and time consuming. Tests are often requested
sequentially and undertaken in different laboratories. This causes prolonged unnecessary presumptive isolation of patients, becausemost cases
are non-infectious. A molecular multiplex test (Luminex Gastrointestinal Pathogen Panel (GPP)) was compared with conventional testing
over 8 months to determine diagnostic accuracy, turnaround times, laboratory costs, use of isolation facilities and user acceptability. A total of
262 (12%) patients had a pathogen detected by conventional methods compared with 483 (22.1%) by GPP. Most additional cases were
detected in patients developing symptoms in the ﬁrst 4 days of admission. Additional cases were detected because of presumed improved
diagnostic sensitivity but also because clinicians had not requested the correct pathogen. Turnaround time (41.8 h) was faster than bacterial
culture (66.5 h) and parasite investigation (66.5 h) but slower than conventional testing for Clostridium difﬁcile (17.3 h) and viruses (27 h). The
test could allow simpliﬁed requesting by clinicians and a consolidated laboratory workﬂow, reducing the overall number of specimens received
by the laboratory. A total of 154 isolation days were saved at an estimated cost of £30 800. Consumables and labour were estimated at
£150 641 compared with £63 431 for conventional testing. Multiplex molecular testing using a panel of targets allowed enhanced detection
and a consolidated laboratory workﬂow. This is likely to be of greater beneﬁt to cases that present within the ﬁrst 4 days of hospital admission.
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Introduction
Infectious gastroenteritis (IG) is caused by a variety of bacteria,
viruses and parasites. In the USA there are an estimated 179
million cases per year, causing 500 000 hospitalizations and
over 5000 deaths [1,2].
Previous studies describe IG epidemiology using various
diagnostic techniques. Most are community-based [3–6], with
few focusing on cases admitted to or acquired in hospitals
[7,8]. Diarrhoea is common in hospitalized patients resulting in
substantial disruption to healthcare providers [9–13]. How-
ever, most patients have a non-infectious aetiology [10] either
due to underlying co-morbidities or treatment with a wide
range of drugs [14].
This has signiﬁcant consequences for infection control. First,
a risk assessment is required for implementation of isolation
precautions, additionally diagnostics are required both to
target appropriate treatment for individual patients and to
identify non-infectious cases that could be removed from
limited isolation facilities.
There are two problems with currently available diagnos-
tics; ﬁrst pathogens are identiﬁed in only 25–58% of cases
[15,16]. This may be the result of a failure to test for particular
agents, poor sensitivity, presence of as yet unknown infectious
agents, and non-infectious causes [2,7,17]. Consequently, there
can be insufﬁcient conﬁdence placed on negative tests to guide
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clinical decisions. Second, multiple assays are required that test
for all likely pathogens and that have turnaround times ranging
from several hours to a few days. Sequential rather than
parallel testing means that many days elapse before all tests are
obtained. More sensitive and rapid molecular assays could
potentially improve this situation [18,19]. Recently, multiplex
panels capable of detecting the most common agents causing
IG have been developed [20–24].
We undertook an 8-month parallel service evaluation study
to assess the feasibility, clinical utility and acceptability of using
a multiplexed molecular assay for IG to direct more appro-
priate use of isolation facilities.
Methods
Setting
The study was conducted in a central London academic hospital,
with 1100 beds and 180 individual isolation rooms. Patients
admitted with or who develop diarrhoea and/or vomiting are
placed in these rooms (with en-suite toilet), and kept there until
at least 48 h following a return to normal bowel habit. If this is
not possible then the patient is placed in a cohorted or an
otherwise unoccupied bay. Protocol approval was obtained
from the London City and East Research Ethics Committee.
Conventional testing
Clinicians were advised to investigate all cases of diarrhoea
(three or more liquid stools in 24 h). Clinicians can select tests
from a menu including bacteria (Campylobacter, Salmonella,
Shigella and Escherichia coli O:157 with Vibrio and Yersinia
species available upon speciﬁc request), norovirus (samples
received from children aged 5 years and under are automat-
ically tested for rotavirus and faecal adenovirus in addition),
parasites and Clostridium difﬁcile testing that is either performed
on request or automatically on samples from patients over the
age of 65 years. Conventional testing was performed 7 days
per week. Clinicians were advised not to send samples for
bacterial culture if the onset of symptoms was >3 days
following hospital admission. Samples were collected into
sterile preservative-free containers and stored at 4°C until
testing was complete, any samples not conforming to the
shape of the container were rejected. All commercial assays
were performed according to manufacturers’ instructions.
Bacteria
Samples were cultured on the following agars: Charcoal
Cefoperazone Desoxycholate for Campylobacter species,
Xylose-Lysine Decarboxylase for Salmonella and Shigella
species and sorbitol MacConkey with ceﬁxime tellutrite for
E. coli O:157. Additionally, samples were enriched using
Selenite-F broth before subculturing onto ABC Harlequin
chromogenic agar (LabM Ltd, Heywood, UK) for Salmonella
species. Presumptive colonies were conﬁrmed by biochemical
identiﬁcation, matrix-assisted laser desorption/ionization–time
of ﬂight mass spectrometry and/or basic serotyping.
Parasites
Samples were concentrated in Paracep SF (DiaSys Ltd.,
Wokingham, UK). Iodine-stained wet mounts were prepared
from the sediments and examined using light microscopy for
helminth ova and larvae and protozoal cysts. Fluorescence
microscopy using phenol-auramine smears were prepared for
Cryptosporidia oocysts.
Viruses
Samples were tested for norovirus using a microwell enzyme
immunoassay (Ridascreen Third generation Norovirus assay;
R-Biopharm, Darmstadt, Germany). An immunochromato-
graphic test (Rida Quick Rotavirus/Adenovirus Combi; R-Bi-
opharm) was used to detect rotavirus and faecal adenovirus.
Clostridium difﬁcile
Samples were tested ﬁrst for glutamate dehydrogenase using a
microwell enzyme immunoassay (C. diff Chek-60; TechLab,
Blacksburg, VA, USA) followed by conﬁrmation of positives
using PCR (GeneXpert, Cepheid; Sunnyvale, CA, USA).
xTAG Gastrointestinal Pathogen Panel testing
xTAG Gastrointestinal Pathogen Panel (Luminex Corporation,
Toronto, Canada) is a multiplex assay that simultaneously
detects Salmonella sp., Shigella sp., Campylobacter sp., C. difﬁcile
(Toxins A and B), enterotoxigenic E. coli sp., E. coli O157,
Shiga-toxin-producing E. coli sp., Vibrio cholerae, Yersinia entero-
colitica, faecal adenovirus 40/41, rotavirus A, norovirus GI/II,
Giardia sp., Entamoeba histolytica and Cryptosporidium sp.
Clinicians were unable to request a GPP test directly, instead
whenever a request for conventional testing was received, a
GPP request was included. Only one GPP test was performed
per 5-day period (deﬁned as a single episode). Results for GPP
C. difﬁcile were not reported or reviewed until after the study
had ended. Clostridium difﬁcile infection is mandatorily report-
able in the UK so the GPP result was withheld to avoid
confusion with the conventional testing algorithm [25].
For laboratory workﬂow reasons GPP samples were
batched for DNA extraction commencing at 4 pm Monday
to Thursday. Further analysis commenced the following
morning with results available around 3 pm. An alternative
10 am run was performed on Fridays allowing reporting late
Friday evening or early Saturday morning.
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Negative GPP tests were communicated electronically to
the requesting clinicians, after ensuring that no positive result
had previously been communicated by any conventional test,
with advice that clinicians could act on the negative results and
remove the patient from isolation. The infectious diseases
team communicated positive tests by telephone to advise on
treatment and infection control management and with a
responsibility to address unexpected or discrepant results
including communication with public health doctors.
Diagnostic agreement
For the purposes of the study it was assumed that all GPP
results were correct and no further discrepant analysis was
undertaken. Positive and negative agreement and j values
were calculated for each target. Sensitivity and speciﬁcity were
not calculated because of the lack of a comparable reference
standard or resolving assay.
Isolation data collection
A subset of patients were tracked within the hospital by
selecting the ﬁrst half of the results from each GPP run as a
representative sample to ﬁt in with available research nurse
resources. Rates of presumptive isolation, time in isolation and
reasons for not de-isolating given a negative result were
determined from these data. This was collected by a research
nurse using computer records and conﬁrmed by daily
telephone calls and/or ward visits.
User acceptance
Towards the end of the study, test requesters were encour-
aged to complete an online questionnaire comprising 18 simple
questions designed to understand users views and opinions of
the clinical value of the GPP test.
Results
A total of 2187 diarrhoeal stool samples were tested using
GPP between November 2011 and July 2012. Of these, 986
(45%) samples originated from inpatients developing symptoms
in the ﬁrst 4 days of admission (where the day of admission is
day 0) or from outpatient clinics (designated community-asso-
ciated (CA) cases). The remaining 1201 (55%) samples were
from inpatients on day 4 or more of admission (designated
hospital-associated (HA) cases).
Diagnostic agreement
During the ﬁrst 2 months some GPP results incompatible
with the clinical ﬁndings and unconﬁrmed with conventional
testing were obtained for Salmonella and Entamoeba histoly-
tica. The rate of detection for these targets was much
greater than expected in our patient population. A target
speciﬁcity issue was identiﬁed with a reagent batch, which
improved with new reagents and software. Eleven of
forty-ﬁve samples initially positive for Salmonella were
negative on retesting, and 44 of 51 samples were negative
for Entamoeba histolytica on retesting. Only updated results
are discussed in this manuscript.
Overall, 262 (12%) patients had a pathogen detected by
conventional methods compared with 483 (22.1%) patients by
GPP. There was a signiﬁcant difference in the proportion of
positive CA cases (28.5%) compared with HA cases (17.1%)
p <0.01. Norovirus and C. difﬁcile were most frequently
detected (8.7% and 5.9%, respectively), in both CA and HA
cases (9.2% and 8.3%, respectively, for norovirus and 5.8% and
6%, respectively, for C. difﬁcile).
There was a signiﬁcant increase in the number of positive
samples detected by GPP compared with conventional testing
for most targets (Fig. 1). The reasons for this were twofold;
ﬁrst a presumed increase in sensitivity of GPP, and second by
testing for agents that had not been speciﬁcally requested by
the referring clinician (improved case-ﬁnding). The majority of
increased detection resulted from a presumed improvement in
sensitivity for norovirus, Campylobacter, Shigella and Salmonella.
Because of a lack of a reference standard resolving assay, it is
not possible to conﬁrm this; indeed there may have been some
GPP false-positive results. There was a signiﬁcant increase in
detection rates through enhanced case-ﬁnding for parasites, all
viruses and C. difﬁcile. Full performance characteristics are
shown in Table 1.
The median age of patients testing positive using GPP was in
agreement with what is known about the epidemiology of IG;
for example the median age of patients with rotavirus was
1 year and the median age of patients with C. difﬁcile was
62.5 years (Tables 2 and 3). Most Campylobacter, Salmonella
and Shigella positives were identiﬁed in samples requested
within 4 days of admission (87%, 57% and 89%, respectively);
however, only 41% of C. difﬁcile and 48% of norovirus cases
had been identiﬁed by this time.
The median clinical turnaround times for each test (in
hours) were: GPP 41.8 (for afternoon testing), C. difﬁcile 17.3,
norovirus 27.3, adenovirus and rotavirus 27, bacterial culture
66.5 and parasite investigation 66.5 h. These ﬁgures include
sample collection and transportation times. The median
laboratory turnaround time (from the start of processing to
result availability) for GPP overall was 26.6 h for the
afternoon run and 10.4 h for the morning run. In 205
(9.4%) of 2187 patients the GPP test was returned the day
after collection and was signiﬁcantly slower than the after-
noon run.
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Coinfections
A total of 41 samples from 40 patients had two or more
pathogens detected by GPP; this includes 28 cases where
C. difﬁcile was detected with another pathogen (norovirus (14
cases), rotavirus (eight cases), Salmonella (ﬁve cases) and
Campylobacter (one case)). Other frequently encountered
combinations included a parasite with Salmonella (three cases),
Shigella (two cases), norovirus (two cases) and Campylobacter
(one case).
Isolation facility usage
Location of patients at the time of communicating a GPP result
was determined for 1031 patients, 409 of whom were CA
cases and 622 were HA cases. Fifty-seven patients with a GPP
result that was positive for a bacterium or virus were isolated
and ﬁve were not isolated. Of the patients with CA disease,
127 (31%) were never isolated, 36 (9%) were not removed
from isolation and 246 (60%) were removed from isolation
following receipt of a negative GPP test. Of the patients with
HA disease, 298 were never isolated (48%), 65 (10%) were not
removed from isolation and 259 (42%) were removed from
isolation following a negative GPP test. A signiﬁcantly higher
proportion of CA compared with HA patients were removed
from isolation in response to a negative GPP result (p <0.01).
Reasons for not removing patients from isolation following a
negative GPP result can be found in the Supporting Informa-
TABLE 1. Comparison of Gastrointestinal Pathogen Panel (GPP) to conventional testing
Target GPP
Conventional
technique
Positive % agreement
(95% CI)c
Negative % agreement
(95% CI)c
Discordance
p valuea
j statistic
(95% CI)Posb Negb
Clostridium difﬁcile Pos 121 10 95.3 (90–98.2) 99.2 (98.5–99.6) 0.455 0.93 (0.9–0.96)
Neg 6 1175
Norovirus Pos 66 79 82.5 (72.4–90.1) 94.2 (92.8–95.4) <0.0001 0.55 (0.48–0.63)
Neg 14 1284
Adenovirus Pos 6 2 100 (54.1–100) 98.9 (96.1–99.9) 0.5 0.85 (0.65–1.05)
Neg 0 181
Rotavirus Pos 13 6 100 (75.3–100) 96.3 (92.2–98.6) 0.031 0.79 (0.64–0.95)
Neg 0 158
Campylobacter Pos 23 37 100 (85.2–100) 97.3 (96.3–98.1) <0.0001 0.54 (0.41–0.67)
Neg 0 1336
Salmonella Pos 11 36 100 (71.5–100) 97.4 (96.4–98.2) <0.0001 0.37 (0.21–0.53)
Neg 0 1349
Shigella Pos 3 11 100 (29.2–100) 99.2 (98.6–99.6) 0.0001 0.35 (0.06–0.64)
Neg 0 1382
Escherichia coli O157 Pos 3 2 100 (29.2–100) 99.9 (99.5–100) 0.5 0.75 (0.41–1.09)
Neg 0 1391
Giardia Pos 1 17 100 (25–100) 92.8 (88.7–95.7) <0.0001 0.1 (0.08 to 0.28)
Neg 0 218
Entamoeba histolytica Pos 0 9 0 (0–97.5) 96.2 (92.9–98.2) 0.022 0.01 (0.02 to 0.01)
Neg 1 226
Cryptosporidium Pos 1 6 100 (25–100) 97.4 (94.5–99.1) 0.031 0.24 (0.15 to 0.64)
Neg 0 229
aMcNemar test, comparing discordant cells (GPP positive, conventional negative) versus (GPP negative, conventional positive).
bPositive or negative test result comparing GPP to conventional testing.
cClopper–Pearson 95% conﬁdence interval.
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FIG. 1. Improved detection of targets using Gastrointestinal Pathogen Panel by increased analytical sensitivity (grey) and enhanced caseﬁnding
(crosshatch).
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tion (Table S1). In 203/2187 (9.3%) episodes for which
laboratory testing was commenced in the afternoon, the
GPP results were returned quicker than conventional bacterial
and viral results compared with 1984/2187 (90.7%) for
morning-commenced testing.
Costings
The total numbers of conventional tests requested for all
patients during the study were as follows: C. difﬁcile: 1268;
norovirus: 1458; combined adenovirus and rotavirus: 183;
culture for bacteria: 1373; microscopy for parasites: 185. Two
conventional tests were performed for every GPP test. Using
an activity-based costing framework the cost of all materials,
labour and overheads for 4467 conventional tests was
£63 431. As only one GPP test was performed in any 5-day
period, regardless of the number of conventional tests that
were requested, a total of 2187 GPP test were undertaken,
costing £150 641 using the same costing framework. For the
990 patients with CA-diarrhoea, GPP cost £68 191 compared
with £29 223 for conventional testing. These ﬁgures do not
include any supplementary work required for positive samples,
e.g. culture and antimicrobial susceptibility testing for Salmo-
nella and Campylobacter. This would result in an additional cost
of £1788 if all bacterially positive GPP targets were cultured.
User acceptability
The GPP test was viewed favourably by test requestors,
particularly for the fast turnaround time and enhanced
infection control action (see Supporting Information, Figure
S1 and Table S2).
TABLE 2. Rates of detection and demographics of community-associated cases
Organism
Number (%) detected
by GPPa
Mean, median
age (years) % male
Median day
of request
Median
LOSb (days)
Median isolation
time (days)
Clostridium difﬁcile 57 (5.8) 47.6, 56 53 1 5 4
Norovirus 90 (9.1) 45.4, 41 48 1 3 3
Adenovirus 8 (0.8) 17.9, 3 50 1 1.5 1
Rotavirus 27 (2.7) 15.2, 1 63 1 2 2
Campylobacter 55 (5.6) 41.2, 41 65 0 3 2
Salmonella 30 (3.0) 25.5, 25 60 1 3 4
Shigella 13 (1.3) 39.4, 46 77 0.5 3 3
Escherichia coli O157 3 (0.3) 16, 14 0 0 16 4
Giardia 14 (1.4) 31.2, 30 86 0 1.5 2
Entamoeba histolytica 6 (0.6) 22.5, 13.5 50 2 1 1
Cryptosporidium 6 (0.6) 56.3, 60.5 50 1 5.5 2
Any organism 282 (28.6) 40.3, 39 56 1 3 3
No organisms 704 (71.4) 47.3, 50 53 1 6 2
Any bacteria 157 (15.9) 40.1, 41 59 1 3 3
Any virus 124 (12.6) 37.5, 35 51 1 3 2.5
Any parasite 25 (2.5) 35.4, 30 68 0 5 1
Two or more
organisms
27 (2.7) 20.7, 1 67 0 3 2.5
All samples 986 45.3, 48 54 1 5 3
aGastrointestinal Pathogen Panel.
bLength of stay.
TABLE 3. Rates of detection and demographics of hospital-associated cases
Organism
Number (%) detected
by GPPa
Mean, median
age (years) % male
Median day
of request
Median
LOSb (days)
Median isolation
time (days)
Clostridium difﬁcile 73 (6) 56.4, 67 49 16 38 10
Norovirus 98 (8.1) 58, 72 47 11 26 8
Adenovirus 3 (0.2) 27.3, 5 67 10 22 9
Rotavirus 10 (0.8) 2.5, 1 80 10 56.5 13
Campylobacter 5 (0.4) 75.4, 82 27 19 21 9
Salmonella 19 (1.6) 22.8, 8 58 7 21 0
Shigella 1 (0.1) 74, 74 100 12 141 4
Escherichia coli O157 2 (0.2) 39, 39 0 57.5 83 6
Giardia 4 (0.3) 60, 61.5 75 21.5 42 8
Entamoeba histolytica 5 (0.4) 54.6, 71 80 13 26 9.5
Cryptosporidium 2 (0.2) 62.5, 62.5 0 17 30.5 13.5
Any organism 201 (16.6) 54.5, 64.5 51 13 32 9
No organisms 1000 (82.6) 55.9, 64 57 12 29 0
Any bacteria 94 (8.0) 52.7, 62.5 50 15 34 9
Any virus 109 (9.0) 53.2, 65 50 10.5 25 8
Any parasite 11 (0.9) 58, 65 64 13 41 8
Two or more organisms 15 (1.2) 35, 29 47 13 22 7
All samples 1210 55.6, 64 47 12 29 0
aGastrointestinal Pathogen Panel.
bLength of stay.
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Discussion
This study provides comprehensive data on the aetiology of IG
in hospitalized patients using a sensitive multiplex molecular
assay. Additionally, it provides unique data on the opportunity
for GPP to improve the use of what are often scarce isolation
facilities by earlier removal of non-infected patients. A
combination of better sensitivity and enhanced case-ﬁnding
improved the identiﬁcation of patients with IG compared with
a battery of conventional techniques. The data conﬁrmed that
most HA-diarrhoea is non-infectious and that the majority of
infectious cases are caused by norovirus or C. difﬁcile. In
contrast, CA-IG was caused by a broader range of agents
(although norovirus and C. difﬁcile were still the most common
organisms). Other studies have found norovirus to be the
leading cause of CA-IG [22,26–29].
Despite the use of GPP, detection of infectious agents was
still low (22.1% overall). Other studies have identiﬁed patho-
gens in a higher proportion of patients: 82% [8] and 37% [30].
It is possible that some patients were infected with agents that
were not included on the panel such as sapovirus [4,19].
Alternatively, it suggests that there is a low pre-test probability
of IG in hospitalized patients who have a sample tested. This is
supported by the observation that almost half of patients with
a negative test were not isolated while awaiting results. This
low prevalence of cases (<2.2% for all pathogens except
C. difﬁcile and norovirus) adversely affects the positive predic-
tive value (PPV) of diagnostic tests. Grouping together several
targets with different populations and resulting prevalence
rates within the same panel can result in large disparities in
PPVs. The poor diagnostic agreement for salmonella in HA
cases was identiﬁed as a concern by some clinicians and public
health doctors during follow up of GPP-identiﬁed cases. Better
clinical prediction tools to help identify which patients to
appropriately investigate could help with demand management
and improve PPVs.
The proportion of additional cases identiﬁed by GPP
through increased case-ascertainment (rather than increased
sensitivity) was much higher for CA cases. Indeed, not
performing GPP on HA cases only missed nine cases.
Therefore, syndromic testing for a large panel of targets
may be best suited for CA cases where the prevalence of a
broader range of pathogens is higher. Testing for the majority
of HA cases could be restricted to C. difﬁcile and norovirus,
avoiding the unfavourable PPVs for uncommonly encountered
pathogens.
A further beneﬁt of a rapid molecular test is the ability to
help exclude bacterial and viral causes of IG in hospitalized
patients, thereby releasing valuable isolation rooms for other
clinical indications; evaluating this potential beneﬁt was a focus
of this study. This requires a rapid turnaround time, a high
negative predictive value and an ability of front line services to
respond effectively to the result.
The laboratory turnaround time for GPP was inﬂuenced by
when the test was started with a morning run faster than an
afternoon one (27.2 vs 41.8 h). The predominant afternoon
start time for GPP prolonged the turnaround time by about
half a day; however, even with a morning run the once-daily
batch-testing approach made GPP effectively a next-day
service for most patients. These practical issues are important
for assessing the beneﬁt of novel diagnostics for improving
infection control practice. A faster laboratory test (<4 h)
performed twice per day would enable a same-day testing
service.
The response of infection control teams to a negative
result depends on a number of factors. A hospital with only
isolation rooms would presumably not move patients with a
negative test but most hospitals, including our own, have a
limited supply of isolation rooms with a hierarchy of need,
placing potential IG close to the top. Universal pre-emptive
isolation of every patient would be impractical, particularly as
the majority of patients tested do not have an infectious
cause and so guidance was for a risk assessment to be made
about the need for isolation at the time of sending a test.
Forty-one per cent of patients were not isolated when the
negative test was returned and only ﬁve patients with a
positive result were on the open ward (two norovirus and
three bacteria). This implies that staff made reasonably
accurate risk assessments, although whether these un-isolated
patients led to transmission or outbreaks is unknown.
Additionally, a third of patients in isolation rooms were not
then de-isolated following a negative test for a variety of
reasons, although the user survey indicated that this was not
due to a lack of conﬁdence in GPP. A saving in isolation days
through use of GPP was therefore available in 50% of
patients. This beneﬁt was greater in CA cases compared with
HA cases (60.1% vs 41.6%) because of a higher level of
pre-emptive isolation in CA cases. This again implies that
there is likely to be a greater beneﬁt of GPP testing, in terms
of isolation day savings, with its use in patients admitted to
hospital with diarrhoea, rather than those who develop
diarrhoea several days after admission. Finally, the laboratory
costs of GPP testing, including the reduction in testing due to
setting a minimum re-testing period, was more than twice as
much as conventional testing. However, there are likely to be
savings made on wards through better side room utilization
that may well more than offset the increased laboratory costs
but this will require a formal health economic evaluation to
determine.
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A limitation of our study is the parallel nature of the design;
although this allowed us to directly compare both sets of
results for the same sample, we were not able to accurately
measure the effect the test results had on isolation behaviour
individually.
In summary, GPP simpliﬁes clinician ordering of laboratory
tests for IG, enables consolidation of laboratory testing, gave
conﬁdence in setting minimum repeat testing times using GPP,
provided opportunity for earlier de-isolation in 50% of
inpatients and rapidly gained the conﬁdence of test requestors.
The low prevalence of bacterial pathogens in HA-IG makes
GPP potentially more appropriate for testing of CA-IG. There
was also a greater opportunity for releasing isolation rooms in
CA cases. Realizing this beneﬁt requires optimization of
laboratory workﬂow and ideally quicker laboratory turn-
around to enable a same-day service.
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Additional Supporting Information may be found in the online
version of this article:
Table S1. Reasons cited for patients with a negative
Gastrointestinal Pathogen Panel test to remain in isolation.
Table S2. User acceptability questionnaire.
Figure S1. Willingness to wait for a test for infectious
gastroenteritis (respondents were asked for the maximum
acceptable time to wait for a laboratory test for infectious
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results).
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